Skip to content
BociMed logo — Delivering Excellence in Drug Research and Development with...

BociMed

Delivering Excellence in Drug Research and Development with Industry-Leading Expertise

Founded 2012 Series B Total: $100.00M Biotechnology, Health Care +1

General Information

Company Name BociMed
Founded Year 2012
Industries Biotechnology, Health Care, Information Technology
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with BociMed. To contact BociMed, visit abc.bocimed.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BociMed compare?

A PDF of BociMed and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BociMed soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BociMed

BociMed is a biotechnology and healthcare startup, founded in 2012 with a focus on drug research and development as well as clinical research. The company's slogan "Delivering Excellence in Drug Research and Development with Industry-Leading Expertise" underscores its commitment to providing premium R&D and outsourcing services for drug discovery, preclinical pharmaceutical research, and development, as well as clinical I-IV trials and registration. BociMed, originally known as Shanghai Maibo Pharmaceutical Technology Co., Ltd., was registered in Jinshan Petrochemical Zone and has since evolved from primarily engaging in raw material sales, drug import registration, and regional cooperation development in China to establishing itself as a high-tech enterprise specializing in drug R&D technical services.

In 2023, the company secured a CNY100.00M Series B investment from Guoxin Investment. Notably, BociMed has garnered recognition as a Shanghai High-tech Enterprise, Shanghai Credit Creation Enterprise, and Shanghai Small and Medium Enterprise Innovation Undertaking Enterprise, demonstrating its commitment to innovation and development within the industry. While the company's headquarters location is not specified, its significant investment and recognition within the industry underscore its growth potential and the confidence of investors in its innovative approach to drug research and development.

Business keywords: Drug Research, Development, Clinical Research, R&D Services, Outsourcing, Preclinical Research, Clinical Trials, Pharmaceutical Technology, High-Tech Enterprise, Innovation, Shanghai, BioPharma, Regulatory Affairs

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B CNY100.00M 1
Guoxin Investment
15 Feb 2023
Series C Undisclosed 4
Hongfu Assets, Zhangjiang Torch Venture Capital Co +2
01 May 2021
Series A Undisclosed 3
Richen Capital, Spinnotec +1
15 Feb 2019

BociMed Alternatives & Competitors

View All Alternatives
BociMed vs

Leading the future of eye care with efficient drug repurposing and fast-tracked clinical advancement...

Series C
11-50 employees
Biotechnology, Health Care
BociMed vs
Metabolon, Inc.
Metabolon, Inc. United States

Providing actionable biological insights to answer the toughest questions in life sciences research...

Grant
198 employees
Biotechnology, Health Care
BociMed vs

Improving preclinical and clinical trial success rates with world-leading biomarkers & specialized l...

Private Equity
224 employees
Biotechnology, Health Care

FAQ About BociMed

Delivering Excellence in Drug Research and Development with Industry-Leading Expertise
BociMed was founded in 2012.
BociMed operates in Biotechnology, Health Care and Information Technology. Its work centres on Drug Research, Development, Clinical Research and R&D Services.
BociMed has completed 3 funding rounds, raising a total of $100.00M. The latest funding stage is Series B.
Top alternatives and competitors to BociMed include Cloudbreak Therapeutics, Metabolon, Inc., Nordic Bioscience, Global Clinical Trials (GCT), Blueberry Therapeutics Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BociMed and Cloudbreak Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BociMed, https://bouncewatch.com/company/bocimed, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout